Cite
Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer
MLA
Harbeck, Nadia, et al. “Patient’s Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.” Breast Care, vol. 8, no. 2, Apr. 2013, pp. 110–20. EBSCOhost, https://doi.org/10.1159/000350777.
APA
Harbeck, N., Blettner, M., Hadji, P., Jackisch, C., Lück, H.-J., Windemuth-Kieselbach, C., Zaun, S., Haidinger, R., Schmitt, D., Schulte, H., Nitz, U., & Kreienberg, R. (2013). Patient’s Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer. Breast Care, 8(2), 110–120. https://doi.org/10.1159/000350777
Chicago
Harbeck, Nadia, Maria Blettner, Peyman Hadji, Christian Jackisch, Hans-Joachim Lück, Christine Windemuth-Kieselbach, Silke Zaun, et al. 2013. “Patient’s Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.” Breast Care 8 (2): 110–20. doi:10.1159/000350777.